In announcement today, Trevana Inc said it had filed Form S-1 with the US Securities and Exchange Commission for its proposed initial public offer of its shares of common stock. There was no determination of the volume of the shares to be put in the IPO or the price range for each share of common stock.

Jefferies LLC and Barclays Capital Inc would act as joint bookrunners for the IPO. Co-managers for the sale are Canaccord Genuity Inc, Needham & Company LLC and JMP Securities LLC. The share offer would only be made through prospectus dissemination. 

Trevana is a biopharmaceutical company operating at the clincal stage of the approval cycle. It discovers, develops and commercializes therapies using the novel approach of targetting G protein coupled receptors. It already has two product candidates for clinical use, namely TRV027 for acute heart failure and TRV130 for severe acute pain management through intravenous means.